(Q38347216)

2 September 2017

title

Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). (English)

1 reference

2 September 2017

Janet A Dunn

3

0 references

Helena Earl

object named as

Helena Earl

15

0 references

Paul D P Pharoah

13

object named as

Paul Pharoah

1 reference

2 September 2017

Carlos Caldas

12

0 references

Chris Twelves

6

object named as

Chris J Twelves

1 reference

2 September 2017

John M S Bartlett

1

1 reference

2 September 2017

Alison F Munro

2

1 reference

2 September 2017

Christopher McConkey

4

1 reference

2 September 2017

Sarah Jordan

5

1 reference

2 September 2017

David A Cameron

7

1 reference

2 September 2017

Jeremy Thomas

8

1 reference

2 September 2017

Fiona M Campbell

9

1 reference

2 September 2017

Daniel W Rea

10

1 reference

2 September 2017

Elena Provenzano

11

1 reference

2 September 2017

Louise Hiller

14

1 reference

2 September 2017

Christopher J Poole

16

1 reference

2 September 2017

publication date

13 January 2010

1 reference

Lancet Oncology Commission

2 September 2017

published in

1 reference

2 September 2017

volume

11

1 reference

2 September 2017

issue

3

1 reference

2 September 2017

page(s)

266-274

1 reference

Molecular portraits of human breast tumours

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970006-1

7 January 2021

Type I receptor tyrosine kinases as predictive or prognostic markers in early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970006-1

7 January 2021

Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970006-1

7 January 2021

Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970006-1

7 January 2021

Topoisomerase IIalpha-positive and BRCA1-negative phenotype: association with favorable response to epirubicin-based regimens for human breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970006-1

7 January 2021

HER-2 and topoisomerase II as predictors of response to chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970006-1

7 January 2021

Targeted therapy in breast cancer: the HER-2/neu gene and protein

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970006-1

7 January 2021

Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970006-1

7 January 2021

Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970006-1

7 January 2021

DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970006-1

7 January 2021

Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970006-1

7 January 2021

Does polysomy of chromosome 17 have a role in ERBB2 and topoisomerase IIalpha expression? Gene, mRNA and protein expression: a comprehensive analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970006-1

7 January 2021

Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970006-1

7 January 2021

Recommendations for collection and handling of specimens from group breast cancer clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970006-1

7 January 2021

Observer variation in immunohistochemical analysis of protein expression, time for a change?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970006-1

7 January 2021

Evaluating HER2 amplification and overexpression in breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970006-1

7 January 2021

Sample size considerations for the evaluation of prognostic factors in survival analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970006-1

7 January 2021

REporting recommendations for tumour MARKer prognostic studies (REMARK)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970006-1

7 January 2021

Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970006-1

7 January 2021

Anthracyclines and the tailoring of treatment for early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970006-1

7 January 2021

retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil:

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970006-1

7 January 2021

HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970006-1

7 January 2021

Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970006-1

7 January 2021

HER2 and responsiveness of breast cancer to adjuvant chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970006-1

7 January 2021

HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970006-1

7 January 2021

HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970006-1

7 January 2021

HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970006-1

7 January 2021

HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970006-1

7 January 2021

Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970006-1

7 January 2021

Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970006-1

7 January 2021

Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970006-1

7 January 2021

10.1016/S1470-2045(10)70006-1

Identifiers

DOI

1 reference

2 September 2017

1 reference